Childhood Medulloblastoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CHL018 MIFTS: 49	Childhood Medulloblastoma Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Childhood Medulloblastoma

MalaCards integrated aliases for Childhood Medulloblastoma:

Name: Childhood Medulloblastoma ¹² ⁵² ¹⁵

Medulloblastoma, Childhood ⁵² ⁷¹

Pediatric Medulloblastoma ¹²

Medulloblastoma Childhood ⁵⁴

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3869

MeSH ⁴³ D008527

NCIt ⁴⁹ C3997

UMLS ⁷¹ C0278510

Sources

Summaries for Childhood Medulloblastoma

MalaCards based summary : Childhood Medulloblastoma, also known as medulloblastoma, childhood, is related to large cell medulloblastoma and nodular medulloblastoma, and has symptoms including vomiting, gait ataxia and headache. An important gene associated with Childhood Medulloblastoma is CRNDE (Colorectal Neoplasia Differentially Expressed), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Temozolomide and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Childhood Medulloblastoma

Diseases related to Childhood Medulloblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)

#	Related Disease	Score	Top Affiliating Genes
1	large cell medulloblastoma	30.4	SUFU MYCN MYC
2	nodular medulloblastoma	30.4	SUFU PTCH1 MYCN GLI2 CTNNB1
3	greig cephalopolysyndactyly syndrome	30.3	SUFU PTCH1 GLI2
4	rhabdoid cancer	30.0	TP53 SMARCA4 CCND1
5	adult medulloblastoma	29.9	SUFU PTCH1 MYCN GLI2 DDX3X
6	familial adenomatous polyposis	29.9	TP53 MYC CTNNB1 CCND1
7	atypical teratoid rhabdoid tumor	29.7	TP53 SMARCA4 ERBB4 CTNNB1 CCND1
8	basal cell nevus syndrome	29.6	TP53 SUFU PTCH1 MYCN MYC GLI2
9	ovarian disease	29.5	TP53 MYC ERBB2 EGFR CCND1
10	malignant glioma	29.3	TP53 TERT EGFR CRNDE
11	brain cancer	29.1	TP53 TERT PTCH1 PDGFRA NTRK3 MYCN
12	rhabdomyosarcoma	29.1	TP53 PTCH1 PDGFRA MYCN MYC EGFR
13	retinoblastoma	29.1	TP53 SMARCA4 MYCN MYC CCND1
14	basal cell carcinoma	29.0	TP53 TERT SUFU PTCH1 MYCN GLI2
15	nasopharyngeal carcinoma	28.8	TP53 TERT MYC ERBB2 EGFR CTNNB1
16	glioma	28.7	TP53 PDGFRA ERBB2 EGFR CRNDE CCND1
17	li-fraumeni syndrome	28.7	TP53 TERT SUFU PTCH1 MYCN MYC
18	meningioma, familial	28.7	TP53 TERT SUFU PTCH1 MYC ERBB2
19	melanoma	28.3	TP53 TERT PDGFRA MYC ERBB4 ERBB2
20	neuroblastoma	28.2	TP53 TERT SMARCA4 PTCH1 NTRK3 MYCN
21	glioblastoma multiforme	28.1	TP53 TERT PDGFRA MYCN MYC ERBB3
22	leukemia, acute myeloid	28.0	TP53 TERT PDGFRA MYCN MYC KMT2D
23	medulloblastoma	27.7	TP53 TERT SUFU SMARCA4 PTCH1 PDGFRA
24	gastric cancer	27.5	TP53 TERT SMARCA4 PTCH1 MYC ERBB3
25	hepatocellular carcinoma	27.1	TP53 TERT SMARCA4 PTCH1 MYC ERBB3
26	ovary leiomyosarcoma	10.6	SUFU PTCH1
27	holoprosencephaly, recurrent infections, and monocytosis	10.6	PTCH1 GLI2
28	cerebral primitive neuroectodermal tumor	10.5	MYCN MYC
29	vulvar intraepithelial neoplasia	10.5	TP53 CTNNB1
30	melanotic medulloblastoma	10.5	SUFU PTCH1 MYCN
31	anal carcinoma in situ	10.5	TP53 MYC
32	squamous blepharitis	10.5	ERBB4 ERBB3
33	vulva basal cell carcinoma	10.5	MYC ERBB2
34	richter's syndrome	10.4	TP53 MYCN MYC
35	calcifying epithelial odontogenic tumor	10.4	TP53 PTCH1 GLI2
36	microform holoprosencephaly	10.4	SUFU PTCH1 GLI2
37	lung acinar adenocarcinoma	10.4	MYC EGFR CTNNB1
38	connective tissue benign neoplasm	10.4	TP53 PTCH1 CTNNB1
39	micronodular basal cell carcinoma	10.4	TP53 PTCH1 GLI2
40	gastric papillary adenocarcinoma	10.4	TP53 ERBB2
41	microcystic stromal tumor	10.4	CTNNB1 CCND1
42	esophageal leukoplakia	10.4	TP53 CCND1
43	her2-receptor positive breast cancer	10.4	ERBB4 ERBB2
44	central nervous system benign neoplasm	10.4	TP53 MYCN CTNNB1
45	acneiform dermatitis	10.4	ERBB4 EGFR
46	acinar cell carcinoma	10.4	TP53 NTRK3 CTNNB1
47	b cell prolymphocytic leukemia	10.4	TP53 MYC
48	esophageal basaloid squamous cell carcinoma	10.4	TP53 EGFR
49	breast squamous cell carcinoma	10.4	TP53 ERBB2
50	basosquamous carcinoma	10.4	TP53 PTCH1

Graphical network of the top 20 diseases related to Childhood Medulloblastoma:

Sources

Symptoms & Phenotypes for Childhood Medulloblastoma

UMLS symptoms related to Childhood Medulloblastoma:

vomiting, gait ataxia, headache

GenomeRNAi Phenotypes related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

²⁶ (show all 14)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	10.2	EGFR
2	Decreased viability	GR00106-A-0	10.2	ERBB3
3	Decreased viability	GR00173-A	10.2	PDGFRA
4	Decreased viability	GR00221-A-1	10.2	EGFR PDGFRA
5	Decreased viability	GR00221-A-2	10.2	ERBB3 NTRK3
6	Decreased viability	GR00221-A-3	10.2	ERBB2 PDGFRA
7	Decreased viability	GR00221-A-4	10.2	EGFR ERBB2 ERBB3 NTRK3 PDGFRA
8	Decreased viability	GR00301-A	10.2	ERBB3
9	Decreased viability	GR00342-S-2	10.2	ERBB3
10	Decreased viability	GR00342-S-3	10.2	ERBB3
11	Decreased viability	GR00402-S-2	10.2	EGFR ERBB2 ERBB3 NTRK3 PDGFRA
12	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	9.65	CTNNB1 EGFR ERBB2 ERBB4 NTRK3
13	Increased cell death HMECs cells	GR00103-A-0	9.43	CTNNB1 EGFR ERBB3 ERBB4 MYC TP53
14	Increased cell viability after pRB stimulation	GR00230-A-1	8.92	EGFR ERBB2 ERBB3 ERBB4

MGI Mouse Phenotypes related to Childhood Medulloblastoma:

⁴⁵ (show all 26)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.53	CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
2	cellular	MP:0005384	10.52	CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
3	growth/size/body region	MP:0005378	10.51	CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
4	behavior/neurological	MP:0005386	10.47	BATF2 CCND1 CTNNB1 ERBB2 ERBB3 ERBB4
5	embryo	MP:0005380	10.47	CTNNB1 DDX3X EGFR ERBB2 ERBB3 ERBB4
6	mortality/aging	MP:0010768	10.47	BATF2 CCND1 CTNNB1 DDX3X EGFR ERBB2
7	craniofacial	MP:0005382	10.46	CCND1 CTNNB1 EGFR ERBB2 ERBB4 GLI2
8	homeostasis/metabolism	MP:0005376	10.46	CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
9	digestive/alimentary	MP:0005381	10.45	CCND1 CTNNB1 EGFR ERBB2 ERBB3 GLI2
10	endocrine/exocrine gland	MP:0005379	10.4	CCND1 CTNNB1 EGFR ERBB2 ERBB3 ERBB4
11	immune system	MP:0005387	10.39	BATF2 CCND1 CTNNB1 EGFR ERBB3 ERBB4
12	nervous system	MP:0003631	10.39	CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
13	hematopoietic system	MP:0005397	10.38	CCND1 CTNNB1 EGFR ERBB4 KMT2D MYC
14	integument	MP:0010771	10.35	CCND1 CTNNB1 EGFR ERBB2 ERBB3 ERBB4
15	muscle	MP:0005369	10.32	CTNNB1 DDX3X EGFR ERBB2 ERBB3 ERBB4
16	normal	MP:0002873	10.3	CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
17	neoplasm	MP:0002006	10.27	CCND1 CTNNB1 EGFR ERBB2 ERBB3 KMT2D
18	limbs/digits/tail	MP:0005371	10.26	CTNNB1 EGFR ERBB2 GLI2 MYC MYCN
19	hearing/vestibular/ear	MP:0005377	10.18	CTNNB1 EGFR GLI2 KMT2D MYC NTRK3
20	liver/biliary system	MP:0005370	10.11	CTNNB1 EGFR MYC MYCN SMARCA4 SUFU
21	no phenotypic analysis	MP:0003012	10.1	CTNNB1 EGFR GLI2 MYC MYCN NTRK3
22	reproductive system	MP:0005389	10.1	CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB4
23	respiratory system	MP:0005388	10.06	CCND1 CTNNB1 EGFR ERBB2 ERBB3 ERBB4
24	pigmentation	MP:0001186	9.97	CTNNB1 EGFR ERBB3 MYC PDGFRA PTCH1
25	skeleton	MP:0005390	9.8	CCND1 CTNNB1 EGFR ERBB2 GLI2 KMT2D
26	vision/eye	MP:0005391	9.32	CCND1 CTNNB1 EGFR GLI2 MYCN NTRK3

Sources

Drugs & Therapeutics for Childhood Medulloblastoma

Drugs for Childhood Medulloblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Temozolomide

Approved, Investigational

Phase 3

85622-93-1

5394

Lomustine

Approved, Investigational

Phase 3

13010-47-4

3950

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

5743

Levoleucovorin

Approved, Investigational

Phase 3

68538-85-2

Ondansetron

Approved

Phase 3

99614-02-5

4595

Granisetron

Approved, Investigational

Phase 3

109889-09-0

3510

Histamine

Approved, Investigational

Phase 3

51-45-6

774

Cyproheptadine

Approved

Phase 3

129-03-3

2913

Calcium

Approved, Nutraceutical

Phase 3

7440-70-2

271

Emodepside

Investigational, Vet_approved

Phase 3

155030-63-0

Anti-Bacterial Agents

Phase 3

Antitubercular Agents

Phase 3

Antioxidants

Phase 3

Chelating Agents

Phase 3

sodium thiosulfate

Phase 3

Antidotes

Phase 3

Hormones

Phase 3

BB 1101

Phase 3

Calcium, Dietary

Phase 3

Autonomic Agents

Phase 3

Emetics

Phase 3

Antiemetics

Phase 3

Neurotransmitter Agents

Phase 3

Gastrointestinal Agents

Phase 3

Histamine H1 Antagonists

Phase 3

Antipruritics

Phase 3

Histamine Phosphate

Phase 3

51-74-1

65513

Histamine Antagonists

Phase 3

Anti-Allergic Agents

Phase 3

Serotonin Antagonists

Phase 3

Serotonin Agents

Phase 3

Serotonin

Investigational, Nutraceutical

Phase 3

50-67-9

5202

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Megestrol acetate

Approved, Investigational, Vet_approved

Phase 2

595-33-5

11683

Arsenic trioxide

Approved, Investigational

Phase 2

1327-53-3

518740

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

5310940 9887054 6857599 43805

Phenylacetic acid

Approved

Phase 2

103-82-2

999

Carmustine

Approved, Investigational

Phase 2

154-93-8

2578

Tamoxifen

Approved

Phase 2

10540-29-1

2733526

Sodium citrate

Approved, Investigational

Phase 2

68-04-2

Aldesleukin

Approved

Phase 2

110942-02-4, 85898-30-2

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Procarbazine

Approved, Investigational

Phase 2

671-16-9

4915

Amifostine

Approved, Investigational

Phase 2

20537-88-6

2141

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Epinephrine

Approved, Vet_approved

Phase 2

51-43-4

5816

Gemcitabine

Approved

Phase 2

95058-81-4

60750

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

446556 60843

Interventional clinical trials:

(show top 50) (show all 99)

#	Name	Status	NCT ID	Phase	Drugs
1	A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma	Unknown status	NCT00053872	Phase 3	cisplatin;lomustine;vincristine sulfate
2	Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]	Unknown status	NCT00392886	Phase 3	carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
3	Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA	Completed	NCT00002875	Phase 3	cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate
4	A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children	Completed	NCT00716976	Phase 3	sodium thiosulfate
5	Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 Months and <3 Years With Non-metastatic Medulloblastoma: A Children&Apos;s Oncology Group Phase III Study	Completed	NCT00006461	Phase 3	cisplatin;cyclophosphamide;vincristine sulfate;etoposide
6	Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy	Completed	NCT01346267	Phase 3
7	A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial	Completed	NCT00085735	Phase 3	Cisplatin;Cyclophosphamide;Lomustine;Vincristine Sulfate
8	A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate	Completed	NCT00336024	Phase 3	etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate
9	Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor	Active, not recruiting	NCT00085202	Phase 3	cisplatin;cyclophosphamide;vincristine
10	Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk	Terminated	NCT01132547	Phase 3	cyproheptadine hydrochloride
11	Management of Children Aged Less Than 3 Years With Brain Tumors	Unknown status	NCT00281905	Phase 2	carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
12	Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Metastatic (M1-3) Medulloblastoma	Unknown status	NCT00276666	Phase 2	cisplatin;lomustine;vincristine sulfate
13	The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia	Completed	NCT00066248	Phase 2	cyproheptadine hydrochloride;megestrol acetate
14	Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors	Completed	NCT00024258	Phase 2	arsenic trioxide
15	A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS	Completed	NCT00002825	Phase 2	docetaxel
16	A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors	Completed	NCT00005952	Phase 1, Phase 2	temozolomide
17	A Phase II Study of Oxaliplatin in Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors	Completed	NCT00047177	Phase 2	Oxaliplatin
18	Phase II Study of Phenylacetate in Pediatric Patients With Central Nervous System Tumors	Completed	NCT00003241	Phase 2	phenylacetate
19	PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS	Completed	NCT00002752	Phase 1, Phase 2
20	Dose-Intensive Melphalan and Cyclophosphamide With Autologous Bone Marrow Rescue for Recurrent Medulloblastoma and Germ Cell Tumors	Completed	NCT00002594	Phase 2	cyclophosphamide;melphalan
21	A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma	Completed	NCT01239316	Phase 2	Vismodegib
22	Treatment Of Recurrent Central Nervous System Primitive Neuroectodermal Tumors (PNETs) In Children And Adolescents A Strategy Including The Use Of High Dose Thiotepa And High Dose Carboplatin	Completed	NCT00025077	Phase 2	carboplatin;cyclophosphamide;thiotepa
23	A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors	Completed	NCT00019422	Phase 2	carboplatin;lobradimil
24	Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation	Completed	NCT00006258	Phase 2	cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
25	A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors	Completed	NCT00006102	Phase 2	becatecarin
26	Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy	Completed	NCT00005955	Phase 2	temozolomide
27	A Phase I/II Feasibility Study of Oral Etoposide Given Concurrently With Radiotherapy Followed With Dose Intensive Adjuvant Chemotherapy for Children With Newly Diagnosed High Stage Medulloblastoma	Completed	NCT00003573	Phase 2	cisplatin;cyclophosphamide;etoposide;vincristine sulfate
28	Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies	Completed	NCT00002608	Phase 2	cisplatin;doxorubicin hydrochloride;tamoxifen citrate
29	Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors	Completed	NCT00014573	Phase 2	carmustine;cisplatin;cyclophosphamide;paclitaxel
30	Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support	Completed	NCT00003846	Phase 2	carboplatin;cyclophosphamide;thiotepa;vincristine sulfate
31	Treatment of Newly Diagnosed Medulloblastoma and Supratentorial PNET in Patients At Least 3 Years With a Phase II Topotecan Window (High-Risk Patients Only), Risk-Adapted Radiation Therapy, and Dose-Intensive Chemotherapy With Peripheral Blood Stem Cell Support	Completed	NCT00003211	Phase 2	amifostine trihydrate;cisplatin;cyclophosphamide;vincristine sulfate
32	An Intergroup Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy Followed by Adjuvant Chemotherapy in Patients With Newly Diagnosed High-Risk Central Nervous System Embryonal Tumors	Completed	NCT00003203	Phase 2	carboplatin;cisplatin;cyclophosphamide;vincristine sulfate
33	Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma	Completed	NCT00002463	Phase 2	MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
34	PBTC-053: A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients With Recurrent SHH Medulloblastoma	Recruiting	NCT03904862	Phase 1, Phase 2	CX 4945
35	A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma	Recruiting	NCT01878617	Phase 2	Cyclophosphamide;Cisplatin;Vincristine;Vismodegib;Pemetrexed;Gemcitabine
36	A Phase II Study of Intraventricular Methotrexate With Systemic Topotecan and Cyclophosphamide in Children With Recurrent or Progressive Malignant Brain Tumors	Active, not recruiting	NCT02684071	Phase 2	Intra thecal methotrexate;topotecan;cyclophosphamide
37	Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial	Active, not recruiting	NCT01217437	Phase 2	Irinotecan Hydrochloride;Temozolomide
38	Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms	Active, not recruiting	NCT00445965	Phase 2
39	Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial	Active, not recruiting	NCT00788125	Phase 1, Phase 2	carboplatin;dasatinib;etoposide phosphate;ifosfamide
40	Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma	Active, not recruiting	NCT00602667	Phase 2	Induction Chemotherapy;Low-Risk Therapy;High-Risk Therapy;Intermediate-Risk Therapy
41	A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-Omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory Medulloblastoma	Not yet recruiting	NCT04167618	Phase 1, Phase 2	177Lu-DTPA-omburtamab
42	Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue	Withdrawn	NCT00003273	Phase 2	carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
43	Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study	Unknown status	NCT00002647	Phase 1	verteporfin
44	Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma	Unknown status	NCT00360854	Phase 1	erlotinib hydrochloride
45	Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors	Completed	NCT00019630	Phase 1	doxorubicin HCl liposome
46	Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents With Refractory Primary CNS Tumors	Completed	NCT00503724	Phase 1	enzastaurin hydrochloride
47	A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas	Completed	NCT00004212	Phase 1	exatecan mesylate
48	A Phase I Pharmacokinetic and Safety Study in Children With Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449	Completed	NCT00822458	Phase 1	vismodegib
49	Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors	Completed	NCT00015899	Phase 1	lonafarnib
50	High Dose Carboplatin Combined With Oral VP-16 In The Treatment Of Pediatric CNS Malignancies	Completed	NCT00053118	Phase 1	carboplatin;etoposide

Search NIH Clinical Center for Childhood Medulloblastoma

Sources

Genetic Tests for Childhood Medulloblastoma

Sources

Anatomical Context for Childhood Medulloblastoma

MalaCards organs/tissues related to Childhood Medulloblastoma:

⁴⁰

Brain, Breast, Lung, Bone, Ovary, Thyroid, Liver

Sources

Publications for Childhood Medulloblastoma

Articles related to Childhood Medulloblastoma:

(show top 50) (show all 209)

#	Title	Authors	PMID	Year
1	Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD. ⁵⁴ ⁶¹	Shalaby T...Grotzer M	20053783	2010
2	RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. ⁵⁴ ⁶¹	von Bueren AO...Grotzer MA	19134217	2009
3	Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. ⁵⁴ ⁶¹	Gilbertson RJ...Lunec J	9731505	1998
4	Expression of the c-Myc protein in childhood medulloblastoma. ⁵⁴ ⁶¹	Bruggers CS...Carroll WL	9482408	1998
5	Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. ⁵⁴ ⁶¹	Gilbertson RJ...Lunec J	9242460	1997
6	Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. ⁶¹	Begemann M...Kurth I	31609649	2020
7	Strategy to minimize radiation burden in infants and high-risk medulloblastoma using intrathecal methotrexate and high-dose chemotherapy: A prospective registry study in Japan. ⁶¹	Yamasaki K...Hara J	31544362	2020
8	[Subgroup-specific genomic alterations and potential prognostic biomarkers in childhood medulloblastomas]. ⁶¹	Menyhart O...Gyorffy B	31821388	2019
9	Childhood medulloblastoma-a single institution's historical perspective on survival and functional morbidity. ⁶¹	Phipps K...Hayward R	31686139	2019
10	Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience. ⁶¹	Kameda-Smith MM...Pediatric Brain Tumour Study Group	31293232	2019
11	Twenty years experience in treating childhood medulloblastoma: Between the past and the present. ⁶¹	Khalil J...Mawei J	31109839	2019
12	Intellectual, educational, and situation-based social outcome in adult survivors of childhood medulloblastoma. ⁶¹	Kieffer V...Dufour C	29336639	2019
13	Survival and prognostic factors in childhood medulloblastoma: A Brazilian single center experience from 1995 to 2016. ⁶¹	Bleil CB...Antunes ACM	31528456	2019
14	Childhood Medulloblastoma Revisited. ⁶¹	Cassia GSE...Patay Z	30516696	2018
15	Pneumolabyrinth, intracochlear and vestibular fluid loss after cochlear implantation. ⁶¹	Moteki H...Usami SI	29680680	2018
16	Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: similar, but not the same. ⁶¹	Huq AJ...Winship IM	29356994	2018
17	National cancer registry and broad institutional cooperation: turning points in treating childhood medulloblastoma in Iran. ⁶¹	Niktoreh-Mofrad N...Qaddoumi I	29804211	2018
18	Study on Contribution of Biological Interpretable and Computer-Aided Features Towards the Classification of Childhood Medulloblastoma Cells. ⁶¹	Das D...Haque I	29974336	2018
19	Neuropsychological consequences of childhood medulloblastoma and possible interventions: A review. ⁶¹	Doger de Speville E...Chevignard M	29716738	2018
20	Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. ⁶¹	Khatua S...Mack SC	29189165	2018
21	Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers. ⁶¹	Taddei PJ...Newhauser WD	30038799	2018
22	First evidence of genotype-phenotype correlations in Gorlin syndrome. ⁶¹	Evans DG...Lear JT	28596197	2017
23	Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. ⁶¹	Schwalbe EC...Clifford SC	28545823	2017
24	Core deficits and quality of survival after childhood medulloblastoma: a review. ⁶¹	Chevignard M...Dellatolas G	31385962	2017
25	Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. ⁶¹	King AA...Packer RJ	28039368	2017
26	Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia. ⁶¹	Rajagopal R...Abdullah WA	28717752	2017
27	Survival in pediatric medulloblastoma: a population-based observational study to improve prognostication. ⁶¹	Weil AG...Fallah A	27981412	2017
28	The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. ⁶¹	Andrade AF...Tone LG	27785591	2017
29	Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. ⁶¹	Andrade AF...Tone LG	27900530	2017
30	Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns. ⁶¹	Indini A...Massimino M	27770281	2017
31	Neurocognitive Function and Health-Related Quality of Life in Pediatric Korean Survivors of Medulloblastoma. ⁶¹	Yoo HJ...Shin HY	27709849	2016
32	Childhood medulloblastoma. ⁶¹	Massimino M...Rutkowski S	27375228	2016
33	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. ⁶¹	Ramaswamy V...Pomeroy SL	27040285	2016
34	Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. ⁶¹	Friedman GK...Gillespie GY	26188016	2016
35	Evolving molecular era of childhood medulloblastoma: time to revisit therapy. ⁶¹	Khatua S	26617331	2016
36	Effect of motivation on academic fluency performance in survivors of pediatric medulloblastoma. ⁶¹	Holland AA...Stavinoha PL	25825959	2016
37	SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma. ⁶¹	Brown AL...Scheurer ME	26400460	2015
38	The use of 5-ALA to assist complete removal of residual non-enhancing part of childhood medulloblastoma: a case report. ⁶¹	Skjoth-Rasmussen J...Nysom K	26070965	2015
39	CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastoma. ⁶¹	Dahlin AM...Melin B	26290144	2015
40	Evidence of high mortality in long term survivors of childhood medulloblastoma. ⁶¹	Ning MS...Shinohara ET	25557108	2015
41	Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue. ⁶¹	Balachandar S...Sklar CA	25346052	2015
42	A rare case of medulloblastoma coexisting with multiple spinal intramedullary tumors. ⁶¹	Rege S...Awasthi R	25832201	2015
43	School Competence and Fluent Academic Performance: Informing Assessment of Educational Outcomes in Survivors of Pediatric Medulloblastoma. ⁶¹	Holland AA...Stavinoha PL	25398080	2015
44	Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. ⁶¹	Smith MJ...Evans DG	25403219	2014
45	Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. ⁶¹	Ramaswamy V...Bouffet E	24616042	2014
46	Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. ⁶¹	Gudrunardottir T...Packer RJ	24569911	2014
47	NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. ⁶¹	Fiaschetti G...Grotzer MA	24708907	2014
48	The biologic era of childhood medulloblastoma and clues to novel therapies. ⁶¹	Khatua S...Zaky W	24754593	2014
49	Hepatic sinusoidal obstruction syndrome during chemotherapy for childhood medulloblastoma: report of a case and review of the literature. ⁶¹	Kotecha RS...Gottardo NG	24276042	2014
50	Increased focal hemosiderin deposition in pediatric medulloblastoma patients receiving radiotherapy at a later age. ⁶¹	Yeom KW...Edwards MS	23992236	2013

Sources

Genes for Childhood Medulloblastoma

Genes related to Childhood Medulloblastoma (0 elite genes):

(show all 24)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CRNDE	Colorectal Neoplasia Differentially Expressed	Protein Coding	150	Experimental evidence: Regulation ³⁸	27383309
2	MYCN	MYCN Proto-Oncogene, BHLH Transcription Factor	Protein Coding	20.7	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	12455884
3	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	20.68	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	2198527 12733375 19134217 (more) 20053783 9482408
4	ERBB4	Erb-B2 Receptor Tyrosine Kinase 4	Protein Coding	17.85	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	9242460 9731505
5	ERBB3	Erb-B2 Receptor Tyrosine Kinase 3	Protein Coding	16.15	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	9242460
6	PTCH1	Patched 1	Protein Coding	13.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	SUFU	SUFU Negative Regulator Of Hedgehog Signaling	Protein Coding	13.17	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	GLI2	GLI Family Zinc Finger 2	Protein Coding	12.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	DDX3X	DEAD-Box Helicase 3 X-Linked	Protein Coding	12.37	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	TP53	Tumor Protein P53	Protein Coding	12.36	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	KMT2D	Lysine Methyltransferase 2D	Protein Coding	11.99	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	CTNNB1	Catenin Beta 1	Protein Coding	11.97	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	NTRK3	Neurotrophic Receptor Tyrosine Kinase 3	Protein Coding	11.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	SMARCA4	SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4	Protein Coding	11.66	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	EGFR	Epidermal Growth Factor Receptor	Protein Coding	11.5	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	11.43	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	BATF2	Basic Leucine Zipper ATF-Like Transcription Factor 2	Protein Coding	11.15	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	10.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	CCND1	Cyclin D1	Protein Coding	10.87	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	TERT	Telomerase Reverse Transcriptase	Protein Coding	10.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	CASP8	Caspase 8	Protein Coding	10.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	10.69	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	CCND2	Cyclin D2	Protein Coding	10.64	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
24	SH3GL1	SH3 Domain Containing GRB2 Like 1, Endophilin A2	Protein Coding	10.36	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Childhood Medulloblastoma

Sources

Expression for Childhood Medulloblastoma

Search GEO for disease gene expression data for Childhood Medulloblastoma.

Sources

Pathways for Childhood Medulloblastoma

Pathways related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show top 50) (show all 88)

#	Super pathways	Score	Top Affiliating Genes
1	Signaling by GPCR ⁶⁵ Show member pathways GPCR downstream signaling ⁶⁵ Signal Transduction ⁶⁵	14.21	TP53 TERT SUFU SMARCA4 PTCH1 PDGFRA
2	Innate Immune System ⁶⁵ Show member pathways Immune System ⁶⁵ Neutrophil degranulation ⁶⁵	14.1	TP53 SMARCA4 PDGFRA MYC ERBB4 ERBB3
3	ERK Signaling ⁶³ Show member pathways ILK Signaling ⁶³ MAPK Signaling ⁶³ Molecular Mechanisms of Cancer ⁶³ Rho Family GTPases ⁶³	13.84	TP53 SUFU PTCH1 PDGFRA NTRK3 MYC
4	GPCR Pathway ⁶³ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶³ Estrogen Pathway ⁶³ NFAT in Immune Response ⁶³ P2Y Receptor Signaling ⁶³ Pancreatic Adenocarcinoma ⁶³ Paxillin Interactions ⁶³ Ras Pathway ⁶³	13.77	TP53 PDGFRA NTRK3 MYC ERBB4 ERBB3
5	PEDF Induced Signaling ⁶³ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶³ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶³ Glucocorticoid Receptor Signaling ⁶³ IL-6 Pathway ⁶³ MIF Mediated Glucocorticoid Regulation ⁶³ MIF Regulation of Innate Immune Cells ⁶³ NFAT Signaling and Lymphocyte Interactions ⁶³ PGC1Alpha Pathway ⁶³ RAR-Gamma-RXR-Alpha Degradation ⁶³ STAT3 Pathway ⁶³	13.75	TP53 SMARCA4 PDGFRA NTRK3 MYC ERBB4
6	Activation of cAMP-Dependent PKA ⁶³ Show member pathways Activation of PKA through GPCR ⁶³ cAMP Pathway ⁶³ PKA Signaling ⁶³	13.62	SUFU PTCH1 PDGFRA NTRK3 ERBB4 ERBB3
7	TGF-Beta Pathway ⁶³ Show member pathways JAK-STAT Pathway ⁶³ JNK Pathway ⁶³ MAPK Family Pathway ⁶³ Regulation of eIF4 and p70S6K ⁶³ SOCS Pathway ⁶³	13.6	TP53 PDGFRA NTRK3 MYC ERBB4 ERBB3
8	Akt Signaling ⁶³ Show member pathways p38 Signaling ⁶³ Tec Kinases Signaling ⁶³	13.48	TP53 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2
9	Cytokine Signaling in Immune system ⁶⁵ Show member pathways Signaling by Interleukins ⁶⁵	13.43	TP53 SMARCA4 PDGFRA MYC ERBB4 ERBB3
10	Nanog in Mammalian ESC Pluripotency ⁶³ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶³ eNOS Signaling ⁶³ GSK3 Signaling ⁶³	13.34	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
11	IL-2 Pathway ⁶³ Show member pathways ErbB Family Pathway ⁶³ ErbB2-ErbB3 Heterodimers ⁶³ ErbB4 Pathway ⁶³ Growth Hormone Signaling ⁶³ HMGB1 Pathway ⁶³ IL-4 Pathway ⁶³ LPS Stimulated MAPK Signaling ⁶³ PACAP Signaling ⁶³ PI3K Signaling in B-Lymphocyte ⁶³ Prolactin Signaling ⁶³ Thrombopoietin Pathway ⁶³ TREM1 Pathway ⁶³ UVC-Induced MAPK Signaling ⁶³	13.28	TP53 MYC ERBB4 ERBB3 ERBB2 EGFR
12	Toll-like Receptor Signaling Pathway ¹ ³⁶ Show member pathways Chagas disease (American trypanosomiasis) ³⁶ Hepatitis B ³⁶ Hepatitis C ³⁶ NOD-like Receptor Signaling Pathways ⁶⁴ Regulation of toll-like receptor signaling pathway ¹	13.18	TP53 MYC EGFR DDX3X CTNNB1 CCND1
13	GAB1 signalosome ⁶⁵ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁵ Negative regulation of the PI3K/AKT network ⁶⁵ PI3K/AKT activation ⁶⁵ PI3K/AKT Signaling in Cancer ⁶⁵ PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁵ PIP3 activates AKT signaling ⁶⁵ Role of LAT2/NTAL/LAB on calcium mobilization ⁶⁵	13.17	TP53 PDGFRA ERBB4 ERBB3 ERBB2 EGFR
14	Human cytomegalovirus infection ³⁶ Show member pathways Human immunodeficiency virus 1 infection ³⁶ Kaposi sarcoma-associated herpesvirus infection ³⁶	13.01	TP53 PDGFRA MYC EGFR CTNNB1 CCND1
15	Actin Nucleation by ARP-WASP Complex ⁶³ Show member pathways Actin Nucleation and Branching ⁶³ CDC42 Pathway ⁶³ RhoA Pathway ⁶³	13.01	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
16	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²² Thyroid cancer ³⁶	12.95	TP53 PDGFRA MYC ERBB2 EGFR CTNNB1
17	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	12.94	TP53 TERT PDGFRA MYC ERBB4 ERBB3
18	NFAT and Cardiac Hypertrophy ⁶³ Show member pathways IGF1R Signaling ⁶³ Signaling Involved in Cardiac Hypertrophy ⁶³	12.93	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
19	MAPK signaling pathway ³⁶ ¹	12.82	TP53 PDGFRA MYC ERBB4 ERBB3 ERBB2
20	Downstream signaling events of B Cell Receptor (BCR) ⁶⁵ Show member pathways Activation of RAS in B cells ⁶⁵ Signaling by the B Cell Receptor (BCR) ⁶⁵	12.81	TP53 PDGFRA ERBB4 ERBB3 ERBB2 EGFR
21	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁵ MET activates STAT3 ⁶⁵ Neurotrophin signaling pathway ³⁶ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.78	TP53 NTRK3 ERBB3 ERBB2 CTNNB1
22	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.76	TP53 TERT SMARCA4 MYC ERBB2 EGFR
23	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	12.75	TP53 PDGFRA ERBB3 ERBB2 EGFR CCND1
24	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶³ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.67	TP53 PDGFRA MYC ERBB2 EGFR CTNNB1
25	ErbB signaling pathway ¹ ³⁶ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ³⁶ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.59	TP53 PDGFRA MYC ERBB4 ERBB3 ERBB2
26	Wnt Signaling Pathways: beta-Catenin-dependent Wnt Signaling ⁶⁴ Show member pathways Basal cell carcinoma ³⁶ Wnt signaling pathway ³⁶	12.58	TP53 SUFU PTCH1 MYC GLI2 CTNNB1
27	mTOR signaling pathway (KEGG) ⁶⁴ Show member pathways mTOR signaling pathway ³⁶	12.57	TP53 PDGFRA ERBB4 ERBB3 ERBB2 EGFR
28	MicroRNAs in cancer ³⁶	12.57	TP53 PDGFRA MYC ERBB3 ERBB2 EGFR
29	Development ERBB-family signaling ²² Show member pathways Development EGFR signaling pathway ²² EGF Pathway ⁶³ EGFR Signaling Pathway ⁶⁶ ErbB receptor signaling network ¹ GRB7 events in ERBB2 signaling ⁶⁵ PLCG1 events in ERBB2 signaling ⁶⁵	12.52	TP53 MYC ERBB4 ERBB3 ERBB2 EGFR
30	WNT Signaling ⁶³	12.5	TP53 SMARCA4 MYC CTNNB1 CCND1
31	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ¹	12.46	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
32	Pathways in cancer ³⁶	12.42	TP53 TERT SUFU PTCH1 PDGFRA MYC
33	JAK-STAT signaling pathway (KEGG) ³⁶ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁵ Jak/STAT Signaling Pathway ⁶⁴	12.41	PDGFRA MYC EGFR CCND1
34	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.41	PDGFRA ERBB3 ERBB2 EGFR CCND1
35	Human T-cell leukemia virus 1 infection ³⁶	12.4	TP53 TERT MYC CCND1
36	Calcium signaling pathway ³⁶ Show member pathways Oxytocin signaling ¹	12.37	PDGFRA ERBB4 ERBB3 ERBB2 EGFR
37	Signaling by ERBB2 ⁶⁵ Show member pathways Downregulation of ERBB2 signaling ⁶⁵ Downregulation of ERBB2-ERBB3 signaling ⁶⁵ ERBB2 Activates PTK6 Signaling ⁶⁵ ERBB2 Regulates Cell Motility ⁶⁵ GRB2 events in ERBB2 signaling ⁶⁵ PI3K events in ERBB2 signaling ⁶⁵ PI3K events in ERBB4 signaling ⁶⁵ SHC1 events in ERBB2 signaling ⁶⁵ SHC1 events in ERBB4 signaling ⁶⁵	12.36	ERBB4 ERBB3 ERBB2 EGFR
38	Immune response IFN alpha/beta signaling pathway ²² Show member pathways Cytokine Network ⁶³ Interferon alpha/beta signaling ⁶⁵ Regulation of IFNA signaling ⁶⁵	12.35	TP53 TERT PDGFRA NTRK3 MYC EGFR
39	Apoptosis Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ NF-kappaB Pathway ⁷⁰	12.35	TP53 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2
40	Wnt / Hedgehog / Notch ⁴	12.31	SUFU PTCH1 GLI2 CTNNB1
41	Wnt Signaling Pathway and Pluripotency ¹ Show member pathways Wnt Signaling Pathway ¹	12.3	TP53 MYC CTNNB1 CCND1
42	Colorectal Cancer Metastasis ⁶³	12.27	TP53 MYC EGFR CTNNB1 CCND1
43	Hippo signaling pathway ³⁶	12.22	MYC GLI2 CTNNB1 CCND1
44	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²² PDGF Pathway ¹	12.21	PDGFRA MYC ERBB2 EGFR
45	Tyrosine Kinases / Adaptors ⁴	12.21	PDGFRA ERBB4 ERBB3 ERBB2 EGFR
46	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.19	ERBB2 EGFR CTNNB1 CCND1
47	Integrated Breast Cancer Pathway ¹	12.17	TP53 SMARCA4 MYC EGFR CTNNB1 CCND1
48	TGF-beta Signaling Pathway (WikiPathways) ¹	12.14	TP53 TERT MYC CCND1
49	Signaling by PTK6 ⁶⁵ Show member pathways PTK6 Activates STAT3 ⁶⁵ PTK6 Down-Regulation ⁶⁵ PTK6 Expression ⁶⁵ PTK6 promotes HIF1A stabilization ⁶⁵ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁵ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁵ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁵ RAS signaling downstream of NF1 loss-of-function variants ⁶⁵	12.12	ERBB4 ERBB3 ERBB2 EGFR CCND1
50	Spinal Cord Injury ¹	12.09	TP53 MYC EGFR CCND1

Sources

GO Terms for Childhood Medulloblastoma

Cellular components related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleus	GO:0005634	10.09	TP53 TERT SUFU SMARCA4 PTCH1 PDGFRA
2	nucleoplasm	GO:0005654	10.07	TP53 TERT SUFU SMARCA4 PDGFRA MYCN
3	nucleolus	GO:0005730	9.88	TP53 TERT SMARCA4 MYCN MYC GLI2
4	protein-containing complex	GO:0032991	9.85	TP53 SMARCA4 PDGFRA MYC EGFR CTNNB1
5	basolateral plasma membrane	GO:0016323	9.72	ERBB4 ERBB3 ERBB2 EGFR CTNNB1
6	basal plasma membrane	GO:0009925	9.26	ERBB4 ERBB3 ERBB2 EGFR
7	receptor complex	GO:0043235	9.1	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR

Biological processes related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show top 50) (show all 56)

#	Name	GO ID	Score	Top Affiliating Genes
1	multicellular organism development	GO:0007275	10.24	TP53 SUFU PDGFRA NTRK3 GLI2 ERBB4
2	cell differentiation	GO:0030154	10.22	TP53 NTRK3 GLI2 EGFR DDX3X CTNNB1
3	positive regulation of transcription by RNA polymerase II	GO:0045944	10.19	TP53 SMARCA4 MYCN MYC KMT2D GLI2
4	phosphorylation	GO:0016310	10.17	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
5	regulation of transcription by RNA polymerase II	GO:0006357	10.16	TP53 SMARCA4 MYCN MYC ERBB2 EGFR
6	negative regulation of transcription by RNA polymerase II	GO:0000122	10.15	TP53 SUFU SMARCA4 PTCH1 MYC GLI2
7	protein phosphorylation	GO:0006468	10.14	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
8	nervous system development	GO:0007399	10.12	SMARCA4 NTRK3 ERBB4 ERBB3 ERBB2 CTNNB1
9	negative regulation of apoptotic process	GO:0043066	10.11	TP53 TERT MYC GLI2 EGFR DDX3X
10	response to drug	GO:0042493	10.06	TP53 PTCH1 MYC CTNNB1 CCND1
11	in utero embryonic development	GO:0001701	10.02	TP53 PTCH1 PDGFRA GLI2 CTNNB1
12	cell proliferation	GO:0008283	10.01	TP53 GLI2 EGFR CTNNB1
13	positive regulation of ERK1 and ERK2 cascade	GO:0070374	10.01	PDGFRA NTRK3 ERBB4 EGFR
14	positive regulation of gene expression	GO:0010628	10.01	TP53 NTRK3 MYCN MYC ERBB3 ERBB2
15	regulation of cell proliferation	GO:0042127	10	TP53 PTCH1 ERBB3 EGFR CTNNB1
16	protein autophosphorylation	GO:0046777	9.99	PDGFRA ERBB4 ERBB2 EGFR
17	positive regulation of protein phosphorylation	GO:0001934	9.99	NTRK3 ERBB4 ERBB2 EGFR CCND1
18	positive regulation of protein kinase B signaling	GO:0051897	9.98	PDGFRA ERBB4 ERBB3 ERBB2 EGFR
19	MAPK cascade	GO:0000165	9.97	PDGFRA MYC ERBB4 ERBB3 ERBB2 EGFR
20	response to estradiol	GO:0032355	9.93	PTCH1 EGFR CTNNB1 CCND1
21	lung development	GO:0030324	9.92	PDGFRA GLI2 EGFR CTNNB1
22	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.91	PDGFRA NTRK3 ERBB4 ERBB3
23	positive regulation of transcription, DNA-templated	GO:0045893	9.91	TP53 SMARCA4 PTCH1 MYCN MYC GLI2
24	positive regulation of cell growth	GO:0030307	9.89	ERBB2 EGFR DDX3X
25	positive regulation of translation	GO:0045727	9.89	MYC ERBB2 DDX3X
26	cellular response to growth factor stimulus	GO:0071363	9.88	ERBB2 EGFR CTNNB1
27	cellular response to drug	GO:0035690	9.88	TP53 MYC EGFR
28	positive regulation of epithelial cell proliferation	GO:0050679	9.88	MYC ERBB2 EGFR CCND1
29	wound healing	GO:0042060	9.88	TP53 PDGFRA ERBB3 ERBB2 EGFR
30	odontogenesis of dentin-containing tooth	GO:0042475	9.87	PDGFRA GLI2 CTNNB1
31	heart development	GO:0007507	9.87	TP53 NTRK3 GLI2 ERBB4 ERBB3 ERBB2
32	positive regulation of fibroblast proliferation	GO:0048146	9.86	PDGFRA MYC EGFR
33	cellular response to epidermal growth factor stimulus	GO:0071364	9.85	ERBB4 ERBB2 EGFR
34	branching involved in ureteric bud morphogenesis	GO:0001658	9.85	PTCH1 MYC CTNNB1
35	peptidyl-tyrosine phosphorylation	GO:0018108	9.85	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
36	dorsal/ventral pattern formation	GO:0009953	9.84	PTCH1 GLI2 CTNNB1
37	cellular response to reactive oxygen species	GO:0034614	9.84	TP53 PDGFRA EGFR
38	positive regulation of pri-miRNA transcription by RNA polymerase II	GO:1902895	9.81	TP53 TERT SMARCA4
39	liver regeneration	GO:0097421	9.81	PTCH1 EGFR CCND1
40	positive regulation of G1/S transition of mitotic cell cycle	GO:1900087	9.81	TERT EGFR DDX3X CCND1
41	regulation of cell motility	GO:2000145	9.76	ERBB4 ERBB3 ERBB2 EGFR
42	ERBB2 signaling pathway	GO:0038128	9.73	ERBB4 ERBB3 ERBB2 EGFR
43	Leydig cell differentiation	GO:0033327	9.72	PDGFRA CCND1
44	negative regulation of cell division	GO:0051782	9.71	PTCH1 MYC
45	mitotic G1 DNA damage checkpoint	GO:0031571	9.7	TP53 CCND1
46	smoothened signaling pathway involved in dorsal/ventral neural tube patterning	GO:0060831	9.7	PTCH1 GLI2
47	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.7	TP53 MYCN EGFR
48	negative regulation of ERBB signaling pathway	GO:1901185	9.69	ERBB2 EGFR
49	mammary gland duct morphogenesis	GO:0060603	9.68	PTCH1 GLI2
50	spinal cord dorsal/ventral patterning	GO:0021513	9.68	SUFU GLI2

Molecular functions related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show all 16)

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	10.35	TP53 TERT SUFU SMARCA4 PTCH1 PDGFRA
2	DNA binding	GO:0003677	10.18	TP53 TERT SMARCA4 MYCN MYC KMT2D
3	transferase activity	GO:0016740	10.16	TERT PDGFRA NTRK3 KMT2D ERBB4 ERBB3
4	ATP binding	GO:0005524	10.11	TP53 SMARCA4 PDGFRA NTRK3 ERBB4 ERBB3
5	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.95	TP53 SMARCA4 MYCN MYC GLI2 BATF2
6	kinase activity	GO:0016301	9.95	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
7	protein kinase binding	GO:0019901	9.93	TP53 SUFU EGFR CTNNB1 CCND1
8	transcription regulatory region DNA binding	GO:0044212	9.85	TP53 KMT2D GLI2 ERBB4
9	protein C-terminus binding	GO:0008022	9.8	TP53 TERT ERBB2 CTNNB1
10	nucleotide binding	GO:0000166	9.8	SMARCA4 PDGFRA ERBB4 ERBB3 ERBB2 EGFR
11	protein kinase activity	GO:0004672	9.8	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
12	protein phosphatase binding	GO:0019903	9.73	TP53 ERBB2 EGFR CTNNB1
13	p53 binding	GO:0002039	9.69	TP53 SMARCA4 NTRK3
14	protein tyrosine kinase activity	GO:0004713	9.63	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
15	transcription factor binding	GO:0008134	9.56	TP53 SUFU SMARCA4 MYC GLI2 DDX3X
16	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.1	PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR

Sources

Sources for Childhood Medulloblastoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia